Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

FDA perspective: enrolment of elderly transplant recipients in clinical trials.

Meyer JM, Archdeacon P, Albrecht R.

Transplantation. 2013 Apr 15;95(7):916-8. doi: 10.1097/TP.0b013e31828279d9.

PMID:
23380880
2.

Understanding risk evaluation and mitigation strategies in organ transplantation.

Gabardi S.

Pharmacotherapy. 2011 Jul;31(7):714-22. doi: 10.1592/phco.31.7.714. Review.

PMID:
21923459
3.
4.

Future immunosuppressive agents in solid-organ transplantation.

Gabardi S, Cerio J.

Prog Transplant. 2004 Jun;14(2):148-56. Review.

PMID:
15264459
5.

A clinical trial primer: historical perspective and modern implementation.

Karsh LI.

Urol Oncol. 2012 Jul-Aug;30(4 Suppl):S28-32. doi: 10.1016/j.urolonc.2011.05.012. Review.

PMID:
22795078
6.

Patient-reported outcomes for acute graft-versus-host disease prevention and treatment trials.

Lee SJ, Williams LA.

Biol Blood Marrow Transplant. 2010 Mar;16(3):295-300. doi: 10.1016/j.bbmt.2009.08.021. Epub 2009 Sep 9. Review.

7.

Generic immunosuppression in solid organ transplantation: a Canadian perspective.

Harrison JJ, Schiff JR, Coursol CJ, Daley CJ, Dipchand AI, Heywood NM, Keough-Ryan TM, Keown PA, Levy GA, Lien DC, Wichart JR, Cantarovich M.

Transplantation. 2012 Apr 15;93(7):657-65. doi: 10.1097/TP.0b013e3182445e9d. Review.

PMID:
22267158
8.

Belatacept: a new biologic and its role in kidney transplantation.

Su VC, Harrison J, Rogers C, Ensom MH.

Ann Pharmacother. 2012 Jan;46(1):57-67. doi: 10.1345/aph.1Q537. Epub 2012 Jan 3. Review.

PMID:
22215686
9.

Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.

Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH.

Mol Interv. 2007 Dec;7(6):325-34. doi: 10.1124/mi.7.6.9. Review.

PMID:
18199854
10.

Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy.

Taylor AL, Watson CJ, Bradley JA.

Crit Rev Oncol Hematol. 2005 Oct;56(1):23-46. Review.

PMID:
16039869
11.

How should efficacy be evaluated in randomized clinical trials of treatments for depression?

Thase ME.

J Clin Psychiatry. 1999;60 Suppl 4:23-31; discussion 32. Review.

12.

Infectious risk in pediatric organ transplant recipients: is it increased with the new immunosuppressive agents?

Renoult E, Buteau C, Lamarre V, Turgeon N, Tapiero B.

Pediatr Transplant. 2005 Aug;9(4):470-9. Review.

PMID:
16048599
13.

Vaccine INDs: review of clinical holds.

Miller DL, Ross JJ.

Vaccine. 2005 Jan 19;23(9):1099-101. Review.

PMID:
15629351
14.

The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force.

Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ; American Academy of Dermatology Association Task Force.

J Am Acad Dermatol. 2006 May;54(5):818-23. Review. No abstract available. Erratum in: J Am Acad Dermatol. 2006 Aug;55(2):271. VanBeek, Marta J [added].

PMID:
16635663
15.

U.S. Food and Drug Administration perspective of the inclusion of effects of low-level exposures in safety and risk assessment.

Gaylor DW, Bolger PM, Schwetz BA.

Environ Health Perspect. 1998 Feb;106 Suppl 1:391-4. Review.

16.

Assessing tumor-related signs and symptoms to support cancer drug approval.

Williams G, Pazdur R, Temple R.

J Biopharm Stat. 2004 Feb;14(1):5-21. Review.

PMID:
15027497
17.

Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA).

Weaver J, Grenade LL, Kwon H, Avigan M.

Dermatol Ther. 2009 May-Jun;22(3):204-15. doi: 10.1111/j.1529-8019.2009.01233.x. Review.

PMID:
19453344
18.

How are drugs approved? Part 3. The stages of drug development.

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2008 Mar;46(3):17-20. Review.

PMID:
18416270
19.

Management of metastatic skin cancers in organ transplant recipients.

Nicholson S.

Cancer Treat Res. 2009;146:467-81. doi: 10.1007/978-0-387-78574-5_39. Review. No abstract available.

PMID:
19415226
20.

Immunosuppression of the elderly kidney transplant recipient.

Danovitch GM, Gill J, Bunnapradist S.

Transplantation. 2007 Aug 15;84(3):285-91. Review.

PMID:
17700150

Supplemental Content

Support Center